Normalizing vasopressor dose to standardize vasopressors practice in septic shock
Normalizing vasopressor dose to standardize vasopressors practice in septic shock
批准号:
9755725
负责人:
Nicholas A Bosch
金额:
$7.22万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-02-15 至 2021-06-27
关键词:
AcuteAcute Respiratory Distress SyndromeAddressAdultBig DataBloodBlood PressureBostonCardiovascular systemClinicalClinical TrialsCritical CareDataData ScienceData SetDatabasesDevelopmentDoseElectroconvulsive TherapyElectronic Health RecordEvaluationFailureFoundationsFundingFutureGoalsHospital MortalityHospitalsHourHypotensionImpairmentIndividualInfectionIntensive Care UnitsK-Series Research Career ProgramsKnowledgeLeadLifeMeasurementMeasuresMedicineMentorsMetabolicMethodologyMethodsNorepinephrineOrganOrgan failureOutcomeOxygenPartial PressurePatient CarePatient-Focused OutcomesPatientsPatternPerfusionPharmaceutical PreparationsPhysiciansResearchResearch PersonnelResolutionScientistSepsisSeptic ShockSeveritiesSeverity of illnessShockStandardizationSupplementationSyndromeTimeTissuesTrainingUniversitiesVariantVasoconstrictor Agentscareercareer developmentclinical careclinical practicecollaborative environmentelectronic dataimprovedindexingmedical schoolsmortalitynovelpreventprognostic significancerandomized trialresearch studyresponseskillsstandardized caretool
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
We propose the “Normalizing vasopressor dose to standardize vasopressors practice in septic shock” study to
improve the standardization and knowledge of vasopressors during septic shock through the development of a
novel measure of vasopressor dose normalized to blood pressure response and through characterization of
vasopressor practice patterns. Sepsis is a common, life-threatening, dysregulated response to infection. Septic
shock is the most severe form of sepsis where circulatory and metabolic failure results in case fatality
approaching 50%. Vasopressor medications operationalize septic shock (septic shock is defined as
hypotension and hyperlactatemia requiring vasopressors to maintain organ perfusion) and vasopressor
choices have important implications for septic shock outcomes. Despite the importance of vasopressors in the
definition and management of septic shock, numerous knowledge gaps regarding vasopressor dosing and the
choice and timing of second vasopressors exist. These vasopressor knowledge gaps prevent standardization
of clinical practice and septic shock trials that hinder progress in improving vasopressor use in septic shock.
Simple measures that normalize dose to response have led to improved standardization and understanding of
disease severity in other critical care syndromes (e.g. PaO2/FiO2 in Acute Respiratory Distress Syndrome) but
no such measure exists in septic shock. We propose two necessary foundational steps to improve the
evaluation and use of vasopressors in septic shock using high-resolution critical care electronic health record
data: 1) develop and validate a measure of vasopressor dose normalized to blood pressure response with
strong predictive validity for septic shock mortality and 2) leverage hospital variation in vasopressor dosing to
determine the optimal timing of second vasopressor initiation when norepinephrine alone is inadequate.
Completion of this proposal will result in better understanding of the relationship between vasopressor dose,
blood pressure response and septic shock mortality, and develop novel tools for both clinicians and clinical
trialists to improve and standardize care. The rich collaborative environment at Boston University School of
Medicine and the individually-tailored gradated training plan outlined in this proposal are ideally suited to
support Dr. Bosch in accomplishing the study aims and to prepare him to apply for Mentored Career
Development funding with the ultimate goal of becoming a physician-scientist specializing in cardiovascular
critical care data science.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金